WO2023180976 - INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME
National phase entry:
Publication Number
WO/2023/180976
Publication Date
28.09.2023
International Application No.
PCT/IB2023/052861
International Filing Date
23.03.2023
Title **
[English]
INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME
[French]
INDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE PROGÉNITRICE HÉMATOPOÏÉTIQUE 1 (HPK1) ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
1ST BIOTHERAPEUTICS, INC.
Inventors
LEE, Jinhwa
KIM, Kyung-Hee
LIM, Keonseung
GADHE, Changdev Gorakshnath
JEON, Yeonguk
HWANG, Yejin
JO, Eunji
GU, Boeun
KIM, Jae Eun
KIM, Misoon
LIM, Seung Mook
Priority Data
63/323,521
25.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2846 | |
| EPO | Filing, Examination, Granting | 18454 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2088 | |
| USA | Filing, Examination, Granting | 7540 |
Total:
33,389
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.[French]
La présente invention concerne un composé de formule (I) ou des sels pharmaceutiquement acceptables de celui-ci, une composition comprenant le composé, des procédés d'utilisation du composé pour le traitement de divers troubles associés à HPK1, et des procédés de préparation de ces composés.